The question behind every COA
The first buyer question is not only what the result says. It is whether the sample represents the batch being discussed.
A sampling plan makes COA evidence defensible by connecting batch definition, sample selection, chain of custody, lab method and result interpretation.
Sampling evidence checklist
A reviewable sampling file should include:
- Batch or lot definition before sampling.
- Sampling date, person, method and location.
- Number of increments or units sampled where relevant.
- Sample ID linked to batch ID and lab submission.
- Chain of custody and sample condition.
- Retain sample status and retest decision rules.
Route impact
For non-medicinal or early diligence, a practical sampling file may be enough to continue commercial review. For medicinal routes, importer and qualified lab expectations may raise the bar.
CannaWorld should show this as conditional route logic instead of one-size-fits-all lab compliance.
GACP/GMP feasibility check
COA sample identity is linked to a defined batch with chain-of-custody evidence.
Evidence: Sampling record, sample ID, lab submission, COA and retain sample log.
COA exists but sample representativeness or chain of custody is weak.
Evidence: Resampling decision and buyer disclosure note.
Medicinal route requires importer/lab-defined sampling and method expectations.
Evidence: Importer testing plan, lab qualification and technical agreement.